Keywords: Merck & Co, R&D pipeline, Dividend, Tredaptive, Suvorexant, Odanacatibe, V503, Bridon, Regulatory filings

Merck & Co highlights pipeline progress; plans eight US filings in 2012-

Article | 11 November 2011

Print This

US pharma giant Merck & Co (NYSE:MRK) hosted an upbeat R&D and Business Briefing yesterday, where it ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in